Tylenol and xarelto?

Who makes Xarelto and how does it compare to Tylenol?

Xarelto is a prescription blood thinner medication manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1]. It is a direct oral anticoagulant (DOAC) that works by inhibiting the activity of certain clotting factors in the blood, thereby reducing the risk of stroke and blood clots associated with atrial fibrillation, pulmonary embolism, and deep vein thrombosis.

On the other hand, Tylenol is a non-prescription pain reliever and fever reducer made by Johnson & Johnson [2]. It is a combination of acetaminophen (also known as paracetamol) and other ingredients. While both medications are used to alleviate symptoms, they serve distinct purposes and have different mechanisms of action.

What is the patent status of Xarelto?

According to DrugPatentWatch.com, the patent for Xarelto (rivaroxaban) was originally filed in 2001 by Janssen Pharmaceutica [3] and has undergone multiple extensions. The patent for the active ingredient is set to expire in 2027 in the United States. However, it is worth noting that pharmaceutical companies can still maintain exclusivity for their products through various mechanisms, including exclusivity under FDA regulations, brand reputation, and other factors.

How does Xarelto compare to other blood thinners?

Xarelto competes with other DOACs such as Eliquis (apixaban) and Pradaxa (dabigatran) in the market. These medications also work by directly inhibiting clotting factors, but they have different formulations and mechanisms of action. Some studies have suggested that Xarelto and other DOACs may have a lower risk of bleeding compared to traditional anticoagulants such as Warfarin [4].

However, it's essential to note that each medication has its own unique risks and benefits, and patients should consult their healthcare provider to determine the most suitable treatment option for their specific condition.

What are the common side effects of Xarelto compared to Tylenol?

Xarelto has a risk of bleeding, which can manifest as nosebleeds, bleeding gums, or gastrointestinal bleeding, among others [5]. On the other hand, Tylenol is known for its rare but potential liver injury, particularly at high doses or in patients with pre-existing liver disease [6]. Both medications have different side effect profiles, and patients should be aware of the potential risks associated with each medication.

Sources:

[1] Janssen Pharmaceuticals. (2022). XARELTO. Retrieved from https://www.xarelto.com/

[2] Johnson & Johnson. (2022). Tylenol. Retrieved from https://www.tylenol.com/

[3] DrugPatentWatch.com. (2022). Patent expiration for XARELTO (rivaroxaban). Retrieved from https://www.drugpatentwatch.com/product/1034

[4] Patel et al. (2013). Rivaroxaban vs. Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine, 369(23), 2166-2175.

[5] Janssen Pharmaceuticals. (2022). XARELTO Full Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/023023s038lbl.pdf

[6] Johnson & Johnson. (2022). Acetaminophen (Tylenol) Package Insert. Retrieved from https://www.tylenol.com/package-insert/package-insert/acetaminophen/